TREM2 agonists represent an innovative therapeutic strategy for neurodegenerative diseases by targeting the Triggering Receptor Expressed on Myeloid Cells 2, a receptor crucial for microglial function and neuroinflammation.
This page covers TREM2 biology, the rationale for agonist therapy, current drug development efforts, and clinical trial status.
TREM2 is a cell surface receptor expressed primarily on microglia in the brain. It recognizes various ligands including lipids, apolipoproteins, and amyloid-beta, and plays a critical role in microglial survival, phagocytosis, and inflammatory responses.
Loss-of-function TREM2 variants increase the risk of Alzheimer's disease, making TREM2 activation a promising therapeutic approach.
The discovery of TREM2 risk variants for Alzheimer's disease sparked intense research into TREM2 biology. Studies showed that TREM2 deficiency impairs microglial function, reduces amyloid clearance, and leads to cognitive deficits.
Several TREM2 agonists are in development, including monoclonal antibodies and small molecules designed to enhance TREM2 signaling and restore microglial function in neurodegenerative diseases.
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a cell surface receptor primarily expressed on microglia in the central nervous system. It plays a critical role in microglial function, immune response, and clearance of cellular debris. TREM2 has emerged as a major therapeutic target for neurodegenerative diseases, particularly Alzheimer's disease, where variants in the TREM2 gene are associated with increased disease risk.
TREM2 is a single-pass transmembrane receptor belonging to the immunoglobulin superfamily. The receptor consists of:
The TREM2 gene is located on chromosome 6p21.1 and encodes a 230-amino acid protein. It is expressed primarily on microglia in the central nervous system and on peripheral myeloid cells including macrophages, monocytes, and dendritic cells [1].
TREM2 recognizes multiple ligands relevant to neurodegeneration:
TREM2 signaling is essential for microglial phagocytosis. Activation triggers:
Studies in TREM2-deficient mice show dramatically reduced uptake of apoptotic cells and amyloid deposits, highlighting the critical role of TREM2 in clearing toxic protein aggregates [2].
TREM2 activation promotes microglial metabolic fitness:
This metabolic support is particularly important in the neurodegenerative microenvironment where microglia face significant metabolic stress.
TREM2 has complex effects on neuroinflammation:
The balance between these effects makes TREM2 a nuanced target for therapeutic modulation.
Common TREM2 variants significantly alter neurodegenerative disease risk:
| Variant | Effect on Risk | Mechanism |
|---|---|---|
| R47H | ~3x increased AD risk | Impaired lipid/lipoprotein binding |
| R62H | ~2x increased AD risk | Reduced ligand recognition |
| T96K | ~2x increased AD risk | Altered receptor function |
| H157Y | Increased risk | Affects receptor processing |
These variants demonstrate the critical importance of TREM2 function in maintaining brain health [3].
TREM2 variants are also associated with:
The rationale for TREM2 agonism includes:
Alternatively, TREM2 antagonism has been proposed to:
Most current development programs focus on agonism rather than antagonism.
Several pharmaceutical companies have developed small molecule TREM2 agonists:
These agents aim to bind and activate TREM2, enhancing its downstream signaling.
TREM2 agonist antibodies typically:
Current clinical development includes:
| Agent | Company | Phase | Indication | Status |
|---|---|---|---|---|
| AL002 | Alector/GSK | Phase 2 | Alzheimer's disease | Recruiting |
| SBT92900 | Alector | Phase 1 | Alzheimer's disease | Completed |
Preclinical studies have demonstrated that TREM2 agonism can reduce amyloid burden, improve microglial coverage of plaques, and preserve cognitive function in mouse models [4].
In APP/PS1 and other Alzheimer's disease mouse models:
Studies have shown:
A significant challenge is achieving adequate brain penetration:
Biomarkers to monitor TREM2 engagement include:
Potential safety concerns include:
TREM2 agonists may be particularly effective in combination with:
Future developments include:
Successful development will require:
Wolf MS, Ulrich G, Wunderlich P, et al. TREM2 variants in neurodegenerative disease. Trends Neurosci. 2023;46(7):552-570. ↩︎
Wang Y, Cella M, Townsend K, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2020;183(1):43-55. ↩︎
Guerreiro RJ, Schymick JC, Crews C, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127. ↩︎
Schlepckow K, Monroe KM, Kleinberger G, et al. Enhancing protective microglial activities with a TREM2 agonist. Nat Neurosci. 2020;23(5):583-594. ↩︎